Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Clinical trial NCT01746836 · RECRUITING

Trial details

NCT number: NCT01746836
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Start date: 2013-01-17
Primary completion: 2030-12-31
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.